TILT won a grant for a 2.5 M€ (~$ 2.9M) project, entitled UNLEASHAD, from the European Commission EIC SME Instrument. The grant will be used to perform a Phase 1 clinical trial with the company’s lead drug, TILT-123. Read the press release here.
Latest News
Upcoming Events
Please contact our business development team to meet us at the following events:
13th November 2023
Investival Showcase 2023
London, England
6-8th December 2023
ESMO IO
Geneva, Switzerland
8-10th January 2024
Biotech Showcase
San Francisco, USA
28-29th February 2024
Sachs Annual European Life Sciences CEO Forum
Zurich, Switzerland
10-12 March 2024
SITC
Miami, USA
18-20th March 2024
BIO-Europe
Barcelona, Spain